Original article
Use of xenogenized (modified) tumor cells for treatment in experimental tumor and in human neoplasia

https://doi.org/10.1016/S0753-3322(00)80070-0Get rights and content

Summary

The need to modify tumor cells in order to render them more “immunogenic” was based on the assumption that normal, nonmodified tumor cells are non or weakly immunogenic and as such are unable to raise an efficient protective immune response. Various methods for “xenogenization” (modification of tumor cells) were suggested: induction of new foreign antigens, treatment with either chemicals or enzymes and use of mutagens. Xenogenized tumor cells by their coupling to proteins, and use of chemicals like DTIC (5-[3,3-dimethyl-1-triazeno]-imidazole-4-carboxamide), TZC (8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4 [3H]-one 8-carbamoyl-3-[2-chloroethyl]imidazole [5,1 -d]-1,2,3,5-tetrazin-4[3H]-one) and antiemetic drugs, were tested in experimental models of murine leukemia. Non-tumorigenic clones, xenogenization with DNA hypomethylating agents, aryl-triazine derivatives and DTIC were evaluated for their induction of protective immune response in murine lymphoma. Murine plasmacytoma cells were used for immunization after treatment with glutaraldehyde. Viral modifications of tumor cells were evaluated for their ability to induce a protective tumor response in model systems of rat fibrosarcoma, liver metastatic rat tumor cells, lymphoid tumor cells and hamster tumor cells. In the case of human cancer, attempts were reported to use DNP-conjugated melanoma cells, mutagenic triazine compounds, an autologous colon tumor cell bacillus Calmette-Guerin (BCG) vaccine and genetically engineered vaccines for immunization. The general conclusion drawn from experimental tumor models and for human cancer is, that although modified tumor cells were found to be partially effective in experimental models, it is still necessary to provide more data in order to determine the effective use of xenogenized human tumor cells for immunotherapy.

References (66)

  • BelladonaML et al.

    A retroviral virus encoded by mutated env p15E gene is recognized by specific CD8+ lymphocytes on drug-treated murine mastocytoma P815

    1nt J Immunopharmacol

    (1996)
  • Ben-EfraimS et al.

    Tumor immuno prophylaxis in mice using glutaraldehyde-treated syngeneic myeloma cells

    Br J Cancer

    (1981)
  • BenjaminiE et al.

    Immunity to lymphoid tumors induced in syngeneic mice by immunization with mitomycin-C-treated cells

    J Immunol

    (1977)
  • BerdHC et al.

    Treatment of human melanoma with a hapten-modified autologous vaccine

    Ann NY Acad Sci

    (1993)
  • BergelM et al.

    Association of tumorigenic and nontumorigenic (immunogenic) variants in a mouse T-cell lymphoma with two distinct p53 mutations

    Mol Carcinog

    (1993)
  • BonmassarE et al.

    Antigenic changes of L1210 leukemic in mice treated with 5(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide

    Cancer Res

    (1972)
  • BonmassarE et al.

    Immuno-logical alterations of leukemic cells in vivo after treatment with an antitumor drug

  • CarlowDA et al.

    Enhanced expression of class I major histocompatibility complex gene (Dk) products on immunogenic variants of a spontaneous murine carcinoma

    J Natl Cancer Inst

    (1985)
  • FiorettiMC et al.

    Xenogenization as a new approach to cancer immunotherapy

  • FiorettiMC et al.

    Antigenic changes of a murine lymphoma by in vivo treatment with triazine derivatives

    Cancer Immunol Immunother

    (1981)
  • FitchnerI et al.

    In vivo characterization of immunogenicity of a mitoxantrone-resistant murine P388 leukemia

    In Vivo

    (1993)
  • GiulianiA et al.

    Chemical xenogenization: antigenic changes of cancer cells induced by triazine compounds

    Contrib Gynecol Obstet

    (1991)
  • GrazianiG et al.

    06-alkylguanine-DNA alkyltransferase attenuates triazene-induced cytotoxicity and tumor cells immunogenicity in murine L1210 leukemia

    Cancer Res

    (1995)
  • GrohmannU et al.

    Endogenous retroviral gp70 genes of the murine lymphoma L5178Y: analysis of restriction fragment polymorphism upon induction of drug mediated immunogenicity

    Viral Immunol

    (1994)
  • HaasC et al.

    Immunogenicity increase of autologous tumor cell vaccines by virus infection and attachment of bispecific antibodies

    Cancer Immunol Immunother

    (1996)
  • HamburgVP et al.

    Artificial heterogenization of tumors by means of herpes simplex and polyoma virus

    Nature (Lond)

    (1964)
  • HannaMG et al.

    Active specific immunotherapy of human colorectal carcinoma with an autologous tumor cell/bacillus Calmette-Guerin vaccine

    Ann NY Acad Sci

    (1993)
  • HauschkaTS

    Immunologic aspects of cancer: a review

    Cancer Res

    (1953)
  • HericourtJ et al.

    De la serotherapie dans le traitement du cancer

    CR Hebd Acad Sci

    (1895)
  • HericourtJ et al.

    Traitement d'un cas de sarcome par la serotherapie

    CR Hebd Acad Sci

    (1895)
  • ItayaT et al.

    Xenogenization of a mouse lung carcinoma (3LL) by transfection with an allogeneic class I histocompatibility complex gene (H-2Ld)

    Cancer Res

    (1987)
  • KleinG

    Xenogenization

    Jpn J Cancer Res

    (1995)
  • KleinG et al.

    Rejectability of virus-induced tumors and nonrejectability of spontaneous tumors: a lesson in contrasts

    Transplant Proc

    (1977)
  • View full text